Madrigal Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024
Ticker: MDGL · Form: 10-Q · Filed: May 7, 2024 · CIK: 1157601
Sentiment: neutral
Topics: 10-Q, Madrigal Pharmaceuticals, Financial Report, Quarterly Earnings, SEC Filing
TL;DR
<b>Madrigal Pharmaceuticals, Inc. filed its Q1 2024 10-Q report detailing financial performance and equity components.</b>
AI Summary
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Madrigal Pharmaceuticals, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing covers the first quarter of fiscal year 2024. The company's principal business is pharmaceutical preparations. The filing includes detailed financial information for the periods ending March 31, 2024, December 31, 2023, and March 31, 2023. Key financial statement components such as common stock, additional paid-in capital, and retained earnings are detailed for these periods.
Why It Matters
For investors and stakeholders tracking MADRIGAL PHARMACEUTICALS, INC., this filing contains several important signals. This 10-Q filing provides investors with the latest quarterly financial data, crucial for assessing the company's performance and making informed investment decisions. The detailed breakdown of equity accounts offers insight into the company's capital structure and how it has evolved over the reported periods.
Risk Assessment
Risk Level: low — MADRIGAL PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not indicate any immediate or significant financial distress or unusual events.
Analyst Insight
Monitor future 10-Q filings for revenue growth, net income trends, and updates on key drug development programs.
Key Numbers
- 2024-03-31 — Period End Date (Quarterly report)
- 2024-05-07 — Filing Date (10-Q filing)
- 2834 — SIC Code (Pharmaceutical Preparations)
- 1231 — Fiscal Year End (Company fiscal year)
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Filer name
- MDGL (company) — Ticker symbol
- 2024-03-31 (date) — Period of report
- 2024-05-07 (date) — Filing date
- 200 BARR HARBOR DRIVE, SUITE 400 (address) — Business address
- WEST CONSHOHOCKEN, PA 19428 (address) — Business address
- SYNTA PHARMACEUTICALS CORP (company) — Former company name
- 2001-08-15 (date) — Date of name change
FAQ
When did MADRIGAL PHARMACEUTICALS, INC. file this 10-Q?
MADRIGAL PHARMACEUTICALS, INC. filed this Quarterly Report (10-Q) with the SEC on May 7, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by MADRIGAL PHARMACEUTICALS, INC. (MDGL).
Where can I read the original 10-Q filing from MADRIGAL PHARMACEUTICALS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by MADRIGAL PHARMACEUTICALS, INC..
What are the key takeaways from MADRIGAL PHARMACEUTICALS, INC.'s 10-Q?
MADRIGAL PHARMACEUTICALS, INC. filed this 10-Q on May 7, 2024. Key takeaways: Madrigal Pharmaceuticals, Inc. filed a 10-Q report for the period ending March 31, 2024.. The filing covers the first quarter of fiscal year 2024.. The company's principal business is pharmaceutical preparations..
Is MADRIGAL PHARMACEUTICALS, INC. a risky investment based on this filing?
Based on this 10-Q, MADRIGAL PHARMACEUTICALS, INC. presents a relatively low-risk profile. The filing is a standard quarterly report (10-Q) and does not indicate any immediate or significant financial distress or unusual events.
What should investors do after reading MADRIGAL PHARMACEUTICALS, INC.'s 10-Q?
Monitor future 10-Q filings for revenue growth, net income trends, and updates on key drug development programs. The overall sentiment from this filing is neutral.
How does MADRIGAL PHARMACEUTICALS, INC. compare to its industry peers?
Madrigal Pharmaceuticals operates within the pharmaceutical industry, focusing on the development and commercialization of novel therapeutics.
Are there regulatory concerns for MADRIGAL PHARMACEUTICALS, INC.?
The company is subject to standard SEC regulations for public companies, including the requirement to file quarterly reports (10-Q) detailing financial performance and business operations.
Industry Context
Madrigal Pharmaceuticals operates within the pharmaceutical industry, focusing on the development and commercialization of novel therapeutics.
Regulatory Implications
The company is subject to standard SEC regulations for public companies, including the requirement to file quarterly reports (10-Q) detailing financial performance and business operations.
What Investors Should Do
- Review the full 10-Q filing for detailed financial statements and management discussion.
- Analyze the company's equity structure changes from prior periods.
- Track future filings for updates on product development and commercialization efforts.
Year-Over-Year Comparison
This filing represents the first quarterly report of fiscal year 2024, providing updated financial data compared to the previous year's Q1 report and the most recent annual report.
Filing Stats: 4,482 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2024-05-07 09:00:37
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 Par Value Per Share MDGL The NASDAQ St
Filing Documents
- mdgl-20240331.htm (10-Q) — 720KB
- mdgl-20240331xex101.htm (EX-10.1) — 148KB
- mdgl-20240331xex102.htm (EX-10.2) — 158KB
- mdgl-20240331xex103.htm (EX-10.3) — 15KB
- mdgl-202403301xex311.htm (EX-31.1) — 10KB
- mdgl-20240331xex312.htm (EX-31.2) — 10KB
- mdgl-20240331xex321.htm (EX-32.1) — 6KB
- mdgl.jpg (GRAPHIC) — 34KB
- mdgl1.jpg (GRAPHIC) — 34KB
- 0001628280-24-020865.txt ( ) — 5124KB
- mdgl-20240331.xsd (EX-101.SCH) — 37KB
- mdgl-20240331_cal.xml (EX-101.CAL) — 47KB
- mdgl-20240331_def.xml (EX-101.DEF) — 179KB
- mdgl-20240331_lab.xml (EX-101.LAB) — 489KB
- mdgl-20240331_pre.xml (EX-101.PRE) — 341KB
- mdgl-20240331_htm.xml (XML) — 464KB
Financial Information
Part I. Financial Information 3 Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited): 3 Condensed Consolidated Balance Sheets at March 31, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 2023 4 Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023 5 Condensed Consolidated Statements of Stockholders' Equity for the Three Months Ended March 31, 2024 and 2023 6 Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 7 Notes to Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.
Controls and Procedures
Controls and Procedures 30
Other Information
Part II. Other Information 31 Item 1.
Legal Proceedings
Legal Proceedings 31 Item 1A.
Risk Factors
Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 33
Signatures
Signatures 36 2 Table of Contents
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION Item1. Financial Statements. MADRIGAL PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited; in thousands, except share and per share amounts) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 622,517 $ 99,915 Marketable securities 436,546 534,216 Inventory 854 — Prepaid expenses and other current assets 14,035 3,150 Total current assets 1,073,952 637,281 Property and equipment, net 1,742 1,553 Intangible assets, net 5,000 — Right-of-use asset 1,586 1,713 Total assets $ 1,082,280 $ 640,547 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 21,528 $ 28,041 Accrued expenses 92,271 89,980 Lease liability 542 527 Total current liabilities 114,341 118,548 Long term liabilities: Loan payable, net of discount 116,135 115,480 Lease liability 1,045 1,186 Total long term liabilities 117,180 116,666 Total liabilities 231,521 235,214 Stockholders' equity: Preferred stock, par value $ 0.0001 per share authorized: 5,000,000 shares at March 31, 2024 and December 31, 2023; 2,369,797 and 2,369,797 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively — — Common stock, par value $ 0.0001 per share authorized: 200,000,000 at March 31, 2024 and December 31, 2023; 20,684,663 and 19,875,427 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 2 2 Additional paid-in-capital 2,334,760 1,741,153 Accumulated other comprehensive income (loss) ( 172 ) 468 Accumulated deficit ( 1,483,831 ) ( 1,336,290 ) Total stockholders' equity 850,759 405,333 Total liabilities and stockholders' equity $ 1,082,280 $ 640,547 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents MADRIGAL PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited; in thousands, except share and per share amounts) Three Months Ended March 31, 2024 2023 R